SG11201901495YA - Method for producing antibody fusion protein - Google Patents

Method for producing antibody fusion protein

Info

Publication number
SG11201901495YA
SG11201901495YA SG11201901495YA SG11201901495YA SG11201901495YA SG 11201901495Y A SG11201901495Y A SG 11201901495YA SG 11201901495Y A SG11201901495Y A SG 11201901495YA SG 11201901495Y A SG11201901495Y A SG 11201901495YA SG 11201901495Y A SG11201901495Y A SG 11201901495YA
Authority
SG
Singapore
Prior art keywords
fusion protein
column chromatography
mammalian cells
producing antibody
antibody fusion
Prior art date
Application number
SG11201901495YA
Other languages
English (en)
Inventor
Yuri Koshimura
Hiroyuki Sonoda
Miroslav Matev
Shinji Kakimoto
Tsuyoshi Fukui
Yukichi Hatano
Original Assignee
Jcr Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jcr Pharmaceuticals Co Ltd filed Critical Jcr Pharmaceuticals Co Ltd
Publication of SG11201901495YA publication Critical patent/SG11201901495YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/069Vascular Endothelial cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/06Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013Iduronate-2-sulfatase (3.1.6.13)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017Lysozyme (3.2.1.17)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201901495YA 2016-08-25 2017-08-25 Method for producing antibody fusion protein SG11201901495YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016164901 2016-08-25
PCT/JP2017/030470 WO2018038243A1 (ja) 2016-08-25 2017-08-25 抗体融合蛋白質の製造方法

Publications (1)

Publication Number Publication Date
SG11201901495YA true SG11201901495YA (en) 2019-03-28

Family

ID=61246169

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901495YA SG11201901495YA (en) 2016-08-25 2017-08-25 Method for producing antibody fusion protein

Country Status (11)

Country Link
US (1) US11512135B2 (enExample)
EP (1) EP3505538B1 (enExample)
JP (2) JP6993814B2 (enExample)
KR (1) KR102318480B1 (enExample)
CN (1) CN109641971B (enExample)
AU (1) AU2017316955B2 (enExample)
BR (1) BR112019003622A2 (enExample)
CA (1) CA3034589A1 (enExample)
MX (1) MX389073B (enExample)
SG (1) SG11201901495YA (enExample)
WO (1) WO2018038243A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY187033A (en) 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
CA2990565A1 (en) 2015-06-24 2016-12-29 Jcr Pharmaceuticals Co., Ltd. Fusion protein containing bdnf and anti-human transferrin receptor antibody
KR102466248B1 (ko) * 2016-12-26 2022-11-10 제이씨알 파마 가부시키가이샤 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체
CN110100000B (zh) 2016-12-26 2023-06-20 Jcr制药股份有限公司 含有bdnf的融合蛋白
US11932699B2 (en) 2017-09-07 2024-03-19 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
JP2019137675A (ja) * 2018-02-05 2019-08-22 Jcrファーマ株式会社 薬剤を筋肉に送達するための方法
EP3560945A1 (en) * 2018-04-27 2019-10-30 F. Hoffmann-La Roche AG Methods for purification of polypeptides using polysorbates
WO2019224660A1 (ja) * 2018-05-24 2019-11-28 HOYA Technosurgical株式会社 吸着剤の生産方法
KR102692543B1 (ko) * 2018-10-26 2024-08-07 재단법인 목암생명과학연구소 Ids를 포함하는 융합 단백질 및 이의 용도
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées
US20240301069A1 (en) * 2020-12-23 2024-09-12 Guangdong Fapon Biopharma Inc. Anti-PD-L1 Antibody and Usethereof
MA71665A (fr) * 2021-02-11 2025-05-30 Denali Therapeutics Inc. Protéines de fusion du récepteur anti-transferrine et leurs procédés d'utilisation
BR112023018268A2 (pt) 2021-03-09 2023-10-31 Japan Chem Res Método para produzir uma proteína de fusão
KR20240125957A (ko) * 2021-12-28 2024-08-20 제이씨알 파마 가부시키가이샤 안전한 유전자 치료를 위한 항트랜스페린 수용체 항체와 생리 활성을 갖는 단백질의 융합 단백질
WO2024010067A1 (ja) * 2022-07-08 2024-01-11 Jcrファーマ株式会社 中枢神経系疾患の治療のための、核酸分子、ベクター、組換え細胞及び薬剤
WO2025137213A1 (en) 2023-12-20 2025-06-26 Denali Therapeutics Inc. Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670931A2 (en) * 2003-09-05 2006-06-21 GTC Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
AR051805A1 (es) * 2004-12-21 2007-02-07 Centocor Inc Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
US20110105734A1 (en) 2006-12-06 2011-05-05 Jcr Pharmaceuticals Co., Ltd. Method for production of human erythropoietin
CN101622274A (zh) * 2006-12-12 2010-01-06 比奥雷克西斯药物公司 转铁蛋白融合蛋白库
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトfshの製造方法
CA2739568C (en) 2008-10-31 2015-12-01 Shujun Sun Purification of acidic proteins using ceramic hydroxyapatite chromatography
HRP20190690T1 (hr) 2009-10-09 2019-06-28 Armagen, Inc. Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
JP6018572B2 (ja) 2011-01-25 2016-11-02 Jcrファーマ株式会社 組換えヒトイズロン酸−2−スルファターゼの製造方法
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
RU2014126482A (ru) * 2011-12-01 2016-01-27 Ангиочем Инк. Нацеленные соединения ферментов и их применение
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
WO2015098989A1 (ja) 2013-12-25 2015-07-02 Jcrファーマ株式会社 血液脳関門を通過する新規抗トランスフェリン受容体抗体
JP6071018B2 (ja) 2014-10-31 2017-02-01 Jcrファーマ株式会社 組換えヒトDNaseIの製造方法
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins

Also Published As

Publication number Publication date
WO2018038243A1 (ja) 2018-03-01
EP3505538A1 (en) 2019-07-03
AU2017316955A1 (en) 2019-03-21
EP3505538B1 (en) 2024-05-01
KR20190040040A (ko) 2019-04-16
BR112019003622A2 (pt) 2019-05-21
EP3505538A4 (en) 2020-03-18
CA3034589A1 (en) 2018-03-01
JP2018033454A (ja) 2018-03-08
US20190225700A1 (en) 2019-07-25
CN109641971B (zh) 2023-04-04
JP6993814B2 (ja) 2022-01-14
KR102318480B1 (ko) 2021-10-28
MX389073B (es) 2025-03-20
US11512135B2 (en) 2022-11-29
JP7232889B2 (ja) 2023-03-03
AU2017316955B2 (en) 2022-03-03
JP2022028959A (ja) 2022-02-16
MX2019002252A (es) 2019-07-04
CN109641971A (zh) 2019-04-16

Similar Documents

Publication Publication Date Title
SG11201901495YA (en) Method for producing antibody fusion protein
PH12021550904A1 (en) Novel crispr/cas12f enzyme and system
MY181513A (en) Cell culture compositions and methods for polypeptide production
EP3539982A3 (en) Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
NZ630568A (en) Methods and means for the production of ch3 domain-comprising molecules
WO2017160360A3 (en) Scalable purification method for aav9
JP2015532096A5 (enExample)
WO2019014310A8 (en) Biological methods for preparing terpenes
PH12015502408A1 (en) Purification of iduronate-2-sulfatase
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
SG10201809452RA (en) Cell culture compositions with antioxidants and methods for polypeptide production
PH12016502406A1 (en) Cell culture process for producing a protein
MX2018004580A (es) Metodo para producir proteina de fusion con dominio fc de igg.
PH12020551655A1 (en) Growth differentiation factor 15 fusion proteins
WO2016149821A8 (en) Methods of making morphinan alkaloids and enzymes therefore
MX2019007411A (es) Reuso de enzimas en glucomanipulacion in vitro de anticuerpos.
WO2019009684A3 (ko) 신규 치료학적 효소 융합단백질 및 이의 용도
EA201000945A1 (ru) Конструирование системы секреции на основе sm-белков
SG11201806843UA (en) Method for producing activated hepatocyte growth factor (hgf)
ZA202107808B (en) Cell culture medium for eukaryotic cells
AU2018276376A1 (en) Cell culture methods
BR112017017303A2 (pt) método para obtenção de clones de células de alta produtividade, linhagem de células de mieloma, e, anticorpo recombinante humanizado.
WO2023167852A3 (en) Cell culture methods for antibody production
WO2011015920A3 (en) A highly efficient process of purification and production of recombinant trastuzumab